Want to see AU:CAN full AI Analyst Report?
Top Page
Cann Group
(Sydney:CAN)
Select Model
Select Model
Rating:53Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance (declining revenue, ongoing operating losses, and persistent negative operating/free cash flow), despite some balance sheet improvement. Valuation is a relative positive due to an extremely low P/E, but technical analysis cannot be assessed due to missing indicators.
Positive Factors
Improved Balance Sheet
The latest balance sheet is materially more manageable than the prior year, when equity was negative and leverage was distorted. A debt-to-equity ratio of about 0.59 provides a stronger capital base and may improve the company’s ability to sustain operations and pursue recovery.
Negative Factors
Declining Revenue
A sharp revenue decline indicates weakening commercial traction in the company’s medicinal cannabis operations and reduces the scale available to absorb fixed costs. Unless reversed, sustained contraction can limit operating leverage, make profitability harder to achieve, and increase dependence on financing or restructuring actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
The latest balance sheet is materially more manageable than the prior year, when equity was negative and leverage was distorted. A debt-to-equity ratio of about 0.59 provides a stronger capital base and may improve the company’s ability to sustain operations and pursue recovery.
Read all positive factors
Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.30M
Dividend YieldN/A
Average Volume (3M)7.26M
Price to Earnings (P/E)0.3
Beta (1Y)0.64
Revenue Growth-24.22%
EPS GrowthN/A
CountryAU
Employees40
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,660,593,600
10 Day Avg. Volume13,637,840
30 Day Avg. Volume7,263,862
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.71
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cann Group Business Overview & Revenue Model
Company Description
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of th...
How the Company Makes Money
Cann Group makes money primarily by selling medicinal cannabis products and/or cannabis-derived inputs (such as dried flower and extracts) produced from its cultivation and manufacturing operations. Revenue is generated through supply arrangements...
Cann Group Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
45
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.56M | 13.25M | 15.37M | 13.78M | 6.41M |
| Gross Profit | -8.06M | 5.15M | -21.75M | 20.63M | 11.24M |
| EBITDA | -6.16M | -8.94M | -35.54M | -24.63M | -24.36M |
| Net Income | 20.30M | -22.34M | -51.24M | -33.79M | -26.47M |
Balance Sheet | |||||
| Total Assets | 51.99M | 78.79M | 92.77M | 129.47M | 139.66M |
| Cash, Cash Equivalents and Short-Term Investments | 490.00K | 10.00K | 1.64M | 765.00K | 1.91M |
| Total Debt | 16.84M | 75.84M | 72.47M | 60.97M | 47.16M |
| Total Liabilities | 23.39M | 81.56M | 78.85M | 70.20M | 54.76M |
| Stockholders Equity | 28.61M | -2.77M | 13.92M | 59.26M | 84.90M |
Cash Flow | |||||
| Free Cash Flow | -1.74M | -9.80M | -17.69M | -25.94M | -65.60M |
| Operating Cash Flow | -1.33M | -9.64M | -15.19M | -22.84M | -20.43M |
| Investing Cash Flow | -406.00K | -157.00K | 1.18M | -28.00K | -45.16M |
| Financing Cash Flow | 2.22M | 8.17M | 14.77M | 21.71M | 64.41M |
Cann Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$57.96M | -15.22 | -1.67% | ― | 15.21% | -141.82% | |
53 Neutral | AU$8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.25M | -2.99 | -9.80% | 10.00% | 5.74% | -222.22% | |
50 Neutral | AU$3.51M | -0.79 | -50.35% | ― | -4.87% | -9.78% | |
50 Neutral | AU$19.38M | -7.34 | -13.81% | 6.27% | 5.93% | 66.32% | |
39 Underperform | AU$18.75M | -5.07 | 4388.00% | ― | -19.29% | 62.42% |
* Healthcare Sector Average
AU:CAN
Cann Group
0.01
>-0.01
-9.09%
AU:EXL
Elixinol Wellness
0.02
<0.01
7.14%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-41.67%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-30.00%
AU:IDT
IDT Australia Limited
0.05
-0.02
-27.69%
AU:VIT
Cronos Australia Ltd.
0.02
-0.05
-70.59%
Cann Group Corporate Events
Cann Group Swings to Profit as Debt Deal and Export Push Reset Its Balance Sheet
Aug 31, 2026
Cann Group has executed a major balance sheet and cost reset, turning a prior-year net deficiency into net assets of $29.1 million and reporting a statutory net profit after tax of $20.3 million. The restructuring included settling $70.6 million o...
Cann Group appoints Stannards Audit as new company auditor
Jul 13, 2026
Cann Group Limited, an Australian medicinal cannabis producer, manufactures and researches cannabis medicines at a large-scale GMP facility near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, along with bulk and white-label cha...
Cann Group Redeems Convertible Notes, Streamlining Capital Structure
Jul 6, 2026
Cann Group Limited operates in the medicinal cannabis sector, focusing on the cultivation and production of cannabis-based products for regulated markets. The company is listed on the ASX under the ticker CAN and manages various forms of capital, ...
Cann Group Secures $2m Increase to Private Credit Loan Facility
Jul 3, 2026
Cann Group Limited has agreed with its private credit lender to increase the total commitment under its existing loan facility by $2 million, less establishment fees, on the same terms as the current arrangement. The additional funding can only be...
Regal Partners exits substantial holding in Cann Group
Jun 29, 2026
Regal Partners Funds Management Pty Ltd and its associates have filed a notice stating they have ceased to be substantial holders in Cann Group Ltd. The change follows a series of share disposals in June 2026, culminating in the sale of more than ...
Cann Group Seeks ASX Quotation for 19.2 Million New Shares
Jun 18, 2026
Cann Group Limited has applied for quotation on the ASX of 19,189,759 ordinary fully paid shares, with an issue date of 18 June 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.